DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH


DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Disposal
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH

25.06.2019 / 12:40
The issuer is solely responsible for the content of this announcement.

Focus on B2B-business

BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH

  • BRAIN thereby withdraws from the loss-making segment of the B2C cosmetics business
  • Focus on growth in the product-scalable B2B product business of the BRAIN Group

Zwingenberg, Germany
25 June 2019

BRAIN AG (together with its subsidiaries the "BRAIN Group" or "BRAIN") has concluded an agreement with Wilde Cosmetics GmbH, Oestrich-Winkel, on the sale of all shares in the loss-making Monteil Cosmetics International GmbH ("Monteil") held by BRAIN to Wilde Cosmetics GmbH. The transaction will be completed on 30 June 2019. The contracting parties have agreed not to disclose financial details.

Monteil Cosmetics International GmbH, based in Düsseldorf, is represented as a brand company in the cosmetics end customer business (B2C). It has been part of the BRAIN Group since 2011. Most recently, BRAIN AG held 68.3% of the Monteil shares, while Wilde Cosmetics GmbH acted as a minority shareholder. The sale of the loss-making investment will unburden the BRAIN Group both financially and in terms of capacity and allow it to concentrate fully on the further expansion of the product-scalable B2B business.

"The focus of the BRAIN Group is on growing the product business with industrial partners. The companies in the BRAIN Group are now fully specialized in R&D and B2B business. This is where we see the absolute strengths of the BRAIN Group, which we are continuously expanding", says Dr. Jürgen Eck, CEO of BRAIN AG.

"We have taken a further step towards consistently implementing our strategy. The pure B2B cosmetics business is and will remain part of the growth strategy", says Ludger Roedder, CBO of BRAIN AG.

"The sale of the Monteil shares has no impact on the forecasts of BRAIN AG for the current 2018/19 financial year. Rather, we confirm the objective of achieving a double-digit growth rate in total operating performance and improved EBITDA at Group level", adds Manfred Bender, CFO of BRAIN AG.



B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.de/en.


Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: ir@brain-biotech.de


This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

25.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 830387

End of News DGAP News Service

830387  25.06.2019 


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 8,76 10,37 21,13 22,79 24,11 27,05 38,56 43,00
EBITDA1,2 -3,72 -3,81 -3,10 -12,36 -7,70 -6,55 -2,47 -0,50
EBITDA-Marge3 -42,47 -36,74 -14,67 -54,23 -31,94 -24,21 -6,41 -1,16
EBIT1,4 -4,39 -4,82 -4,57 -13,81 -9,37 -9,57 -7,17 -3,70
EBIT-Marge5 -50,11 -46,48 -21,63 -60,60 -38,86 -35,38 -18,59 -8,60
Jahresüberschuss1 0,00 -4,52 -5,47 -14,43 -9,40 -8,37 -10,49 -4,90
Netto-Marge6 0,00 -43,59 -25,89 -63,32 -38,99 -30,94 -27,20 -11,40
Cashflow1,7 -4,85 -3,90 -4,11 -8,68 -5,80 -5,42 -3,38 -1,10
Ergebnis je Aktie8 -0,28 -0,33 -0.36 -0,97 -0,58 -0,45 -0,58 -0,27
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotechology
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 8,600 155,28
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 17,17 0,000 -18,03
12,69 - 4,03 -69,979
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 05.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2020 29.05.2020 31.08.2020 14.01.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
9,76% -8,70% -20,37% -13,22%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN